Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:DNLI NASDAQ:RXRX NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$21.25+7.5%$16.34$8.03▼$21.29$2.37B2.061.97 million shs2.79 million shsDNLIDenali Therapeutics$15.20+1.9%$14.39$10.57▼$33.33$2.18B1.32.27 million shs1.61 million shsRXRXRecursion Pharmaceuticals$5.52+8.2%$5.12$3.79▼$12.36$2.21B0.9129.21 million shs58.03 million shsSAGESage Therapeutics$8.68$8.88$4.62▼$11.44$543.54M0.263.63 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+7.54%+27.02%+38.71%+54.94%+107.72%DNLIDenali Therapeutics+1.95%+13.18%-1.62%+3.44%-47.64%RXRXRecursion Pharmaceuticals+8.24%+19.22%+18.45%+4.94%-9.66%SAGESage Therapeutics0.00%0.00%0.00%-5.60%+24.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$21.25+7.5%$16.34$8.03▼$21.29$2.37B2.061.97 million shs2.79 million shsDNLIDenali Therapeutics$15.20+1.9%$14.39$10.57▼$33.33$2.18B1.32.27 million shs1.61 million shsRXRXRecursion Pharmaceuticals$5.52+8.2%$5.12$3.79▼$12.36$2.21B0.9129.21 million shs58.03 million shsSAGESage Therapeutics$8.68$8.88$4.62▼$11.44$543.54M0.263.63 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+7.54%+27.02%+38.71%+54.94%+107.72%DNLIDenali Therapeutics+1.95%+13.18%-1.62%+3.44%-47.64%RXRXRecursion Pharmaceuticals+8.24%+19.22%+18.45%+4.94%-9.66%SAGESage Therapeutics0.00%0.00%0.00%-5.60%+24.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.86Moderate Buy$19.80-6.82% DownsideDNLIDenali Therapeutics 3.12Buy$33.50120.39% UpsideRXRXRecursion Pharmaceuticals 2.40Hold$7.2531.34% UpsideSAGESage Therapeutics 1.93Reduce$7.85-9.56% DownsideCurrent Analyst Ratings BreakdownLatest SAGE, ARQT, RXRX, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight8/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/7/2025ARQTArcutis BiotherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $22.007/28/2025DNLIDenali TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/25/2025ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$18.007/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.007/8/2025SAGESage TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.207/3/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$5.00(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M12.96N/AN/A$1.35 per share15.74DNLIDenali Therapeutics$330.53M6.72N/AN/A$8.53 per share1.78RXRXRecursion Pharmaceuticals$58.84M40.73N/AN/A$2.61 per share2.11SAGESage Therapeutics$41.24M13.18N/AN/A$5.89 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%10/28/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)SAGESage Therapeutics-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%11/4/2025 (Estimated)Latest SAGE, ARQT, RXRX, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/28/2025Q3 2025ARQTArcutis Biotherapeutics-$0.09N/AN/AN/A$86.69 millionN/A8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million7/30/2025Q2 2025SAGESage Therapeutics-$0.96-$0.79+$0.17-$0.79$16.69 million$31.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.773.203.04DNLIDenali Therapeutics0.0110.2710.27RXRXRecursion Pharmaceuticals0.023.583.58SAGESage TherapeuticsN/A9.169.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ADNLIDenali Therapeutics92.92%RXRXRecursion Pharmaceuticals89.06%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%DNLIDenali Therapeutics12.50%RXRXRecursion Pharmaceuticals8.43%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.90 million108.63 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableSAGE, ARQT, RXRX, and DNLI HeadlinesRecent News About These CompaniesBiogen’s Zurzuvae approved as first postpartum depression drug in EuropeSeptember 18, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric PortfolioSeptember 2, 2025 | finance.yahoo.comUK Regulator Approves Biogen’s Drug For Treating Postnatal DepressionAugust 27, 2025 | msn.comReunion’s psychedelic drug headed to late-stage testingAugust 18, 2025 | yahoo.comWhy Are Supernus Pharmaceuticals (SUPN) Shares Soaring TodayAugust 6, 2025 | finance.yahoo.comSage (SAGE) Q2 Revenue Jumps 264%August 1, 2025 | aol.comASupernus strengthens neuropsychiatric portfolio with Sage TherapeuticsAugust 1, 2025 | finance.yahoo.comSage Therapeutics Announces Second Quarter 2025 Financial ResultsJuly 31, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue EstimatesJuly 30, 2025 | zacks.comEurope's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug YeytuoJuly 25, 2025 | fiercepharma.comFSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.comBeyond The Numbers: 6 Analysts Discuss Sage Therapeutics StockJuly 9, 2025 | nasdaq.comScotiabank Downgrades Sage Therapeutics (SAGE)July 9, 2025 | msn.comRx Rundown: AbbVie, Healthline, Beckley Psytech and moreJuly 3, 2025 | mmm-online.comMSage’s Search for Lifeline Ran Into Defiant Biogen CEOJuly 3, 2025 | biospace.comBM&A ramped up in June, with blueBird, Sage and Snyk tie-upsJuly 2, 2025 | bizjournals.comBoston-area pharma company to lay off entire 300-person staff after saleJuly 1, 2025 | msn.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)July 1, 2025 | globenewswire.comWhat Makes Sage Therapeutics (SAGE) a New Buy StockJuly 1, 2025 | zacks.comSage Therapeutics cuts most of its workforce following acquisitionJuly 1, 2025 | statnews.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAGE, ARQT, RXRX, and DNLI Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$21.25 +1.49 (+7.54%) Closing price 10/2/2025 04:00 PM EasternExtended Trading$21.40 +0.15 (+0.71%) As of 10/2/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Denali Therapeutics NASDAQ:DNLI$15.20 +0.29 (+1.95%) Closing price 10/2/2025 04:00 PM EasternExtended Trading$15.48 +0.28 (+1.84%) As of 10/2/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Recursion Pharmaceuticals NASDAQ:RXRX$5.52 +0.42 (+8.24%) Closing price 10/2/2025 04:00 PM EasternExtended Trading$5.54 +0.02 (+0.36%) As of 10/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Sage Therapeutics NASDAQ:SAGESage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding General Dynamics Hits New Highs: Why It Might Keep Climbing Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry Nike’s Turnaround: If the Shoe Fits, Buy It! Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
